<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Visual release hallucinations (Charles Bonnet syndrome)
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Visual release hallucinations (Charles Bonnet syndrome)
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Visual release hallucinations (Charles Bonnet syndrome)
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Victoria S Pelak, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Paul W Brazis, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Janet L Wilterdink, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Aug 31, 2021.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         The Charles Bonnet syndrome (CBS) refers to symptoms of visual hallucinations that occur in patients with visual acuity loss or visual field loss. These are often called release hallucinations, reflecting the most widely accepted theory of their pathogenesis.
        </p>
        <p>
         Underlying conditions of vision loss associated with the CBS affect the eye, optic nerve, or brain and include a diverse set of pathologies, such as macular degeneration and stroke. While often not functionally disabling, the hallucinations can be distressing to patients and negatively impact quality of life [
         <a href="#rid1">
          1
         </a>
         ]. Published case reports suggest that the syndrome is not well recognized by clinicians and may often be misdiagnosed as psychosis or early dementia [
         <a href="#rid2">
          2,3
         </a>
         ].
        </p>
        <p>
         The pathophysiology, causes, clinical features, diagnosis, and treatment of the CBS will be reviewed here. Other causes and the overall approach to visual hallucinations are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/5255.html" rel="external">
          "Approach to the patient with visual hallucinations"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          EPIDEMIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         The CBS may be more common than is generally appreciated. Visual hallucinations are often unreported by patients because they fear that they represent psychiatric disease [
         <a href="#rid1">
          1,4,5
         </a>
         ]. When this symptom is specifically solicited in older patients with impaired vision, 11 to 15 percent admit to having visual hallucinations [
         <a href="#rid1">
          1,5-12
         </a>
         ]. These surveys also reveal that most patients had failed to report these symptoms to their clinician or to family members. One study found that only 12 percent of patients attending a retinal clinic were aware of the condition [
         <a href="#rid13">
          13
         </a>
         ].
        </p>
        <p>
         Patients with more significant vision loss may be more likely to experience and report visual hallucinations. In one survey of patients diagnosed with macular disease, the reported prevalence was 39 percent [
         <a href="#rid14">
          14
         </a>
         ], and among patients with glaucoma attending a visual rehabilitation program, the prevalence was 20 percent [
         <a href="#rid15">
          15
         </a>
         ].
        </p>
        <p>
         Release hallucinations have been reported in all age groups, including children [
         <a href="#rid9">
          9,16
         </a>
         ]. However, most patients with CBS are older adults; in large case series, the mean age is between 70 and 85 years [
         <a href="#rid4">
          4,9,17,18
         </a>
         ]. This probably reflects the mean age at which the most common underlying conditions causing vision loss are seen. Some investigators, but not others, have found that advanced age is a risk factor for release hallucinations within their study population [
         <a href="#rid7">
          7,12,19
         </a>
         ].
        </p>
        <p>
         Other conditions that are inconsistently found to be risk factors for CBS include cognitive impairment, cerebrovascular disease, cortical atrophy on brain imaging, and social deprivation [
         <a href="#rid7">
          7,8,18-22
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h1">
          PATHOPHYSIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with visual acuity loss or visual field loss from any cause, affecting any part of the visual pathway from the eye to the visual cortex, can develop visual hallucinations [
         <a href="#rid4">
          4
         </a>
         ]. Common underlying conditions include age-related macular degeneration, glaucoma, diabetic retinopathy, and cerebral infarction [
         <a href="#rid1">
          1,4,5,9,14,23
         </a>
         ]. However, these hallucinations have been reported to occur in virtually every acquired disorder affecting the visual system [
         <a href="#rid9">
          9
         </a>
         ]. CBS does not occur with congenital blindness.
        </p>
        <p>
         The most widely accepted theory is that the hallucinations occur when visual sensory deafferentation leads to disinhibition of visual cortical regions, which then fire spontaneously [
         <a href="#rid17">
          17,24-26
         </a>
         ]. Similar hallucinations have been reported by individuals subjected to visual deprivation experiments [
         <a href="#rid9">
          9
         </a>
         ]. Functional neuroimaging studies offer some support for this theory [
         <a href="#rid20">
          20,27,28
         </a>
         ]. In four patients with CBS, functional magnetic resonance imaging revealed that active hallucinations were associated with spontaneous activity in the ventral occipital lobe [
         <a href="#rid27">
          27
         </a>
         ]. The content of the hallucinations was associated with specific regional activation that correlated with the known specialized function of that area of the visual cortex.
        </p>
        <p>
         The neurobiology underlying visual hallucinations in CBS remains to be elucidated. In other settings, outside the visual system, deafferentated neurons have been associated with a variety of biochemical, morphologic, and neurophysiologic changes that suggest a phenomenon of denervation hypersensitivity [
         <a href="#rid25">
          25
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h1">
          CLINICAL FEATURES
         </span>
        </p>
        <p class="headingAnchor" id="H4250361202">
         <span class="h2">
          Association with underlying visual disorder
         </span>
         <span class="headingEndMark">
          —
         </span>
         CBS may occur in association with acute or chronic ocular disease.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For patients with chronic ocular disease, the diagnosis of ocular disease is generally established for at least one year before hallucinations emerge [
         <a href="#rid1">
          1,8,9
         </a>
         ]. The likelihood of release hallucinations increases with lower visual acuity [
         <a href="#rid4">
          4,19
         </a>
         ]. While there is no clear threshold of visual acuity loss, the prevalence of hallucinations appears to increase with acuity worse than 20/60 [
         <a href="#rid7">
          7,8
         </a>
         ]. CBS is also more likely to occur with binocular versus monocular disease [
         <a href="#rid1">
          1,8,9
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         By contrast, when release hallucinations occur in the setting of acute cerebral or optic nerve injury (eg, optic neuritis, stroke, surgery), they often occur concomitantly with the vision loss or after a latency of a few hours or days [
         <a href="#rid10">
          10,23,29-32
         </a>
         ]. Latencies of more than several months have also been reported [
         <a href="#rid33">
          33-36
         </a>
         ]. A large visual field deficit is not required [
         <a href="#rid10">
          10
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2530134186">
         <span class="h2">
          Content of hallucinations
         </span>
         <span class="headingEndMark">
          —
         </span>
         Release hallucinations can be simple, nonformed images such as lines, light flashes, or geometric shapes, or they can be complex, formed images of people, animals, or scenes [
         <a href="#rid19">
          19,24,29,31
         </a>
         ]. In a series of 59 patients with release hallucinations due to loss of vision from retinal or neurologic causes, simple hallucinations were more common than complex hallucinations (90 versus 37 percent) [
         <a href="#rid19">
          19
         </a>
         ]. The location of injury within the visual system did not determine the nature of the hallucinations. Others report a higher proportion of complex hallucinations [
         <a href="#rid1">
          1
         </a>
         ]. The content of the simple or complex hallucinations is variable, even for individual patients [
         <a href="#rid4">
          4,5,9
         </a>
         ]. Although some patients perceive the same hallucination each time, they usually do not recur in a stereotyped fashion, a feature that distinguishes them from epileptic hallucinations.
        </p>
        <p>
         There are no associated auditory or other sensory modality hallucinations.
        </p>
        <p>
         The images are usually colored and may be static, animated, or move en bloc across the visual field [
         <a href="#rid5">
          5,8,9
         </a>
         ]. The location of the hallucinations typically corresponds to the underlying vision loss, and as a result, can be monocular or binocular and/or restricted to one-half of the visual field [
         <a href="#rid19">
          19,23,29,31,37
         </a>
         ].
        </p>
        <p>
         The content of the hallucinations usually does not have emotional impact or personal meaning for the patient who almost always recognizes them as unreal [
         <a href="#rid1">
          1,4,5,19
         </a>
         ]. Despite this, a significant number of patients are distressed by their symptoms [
         <a href="#rid14">
          14,23
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H4084693628">
         <span class="h2">
          Other features
         </span>
         <span class="headingEndMark">
          —
         </span>
         Hallucinations occur more often with the eyes open than closed [
         <a href="#rid4">
          4
         </a>
         ], and patients often describe seeing the hallucinations when they are looking at a white background such as a wall, ceiling, or piece of paper. The hallucination will often disappear if the patient closes his or her eyes or looks away [
         <a href="#rid29">
          29
         </a>
         ]. In one study of 60 patients with CBS, most complex hallucinations occurred in the setting of sensory deprivation (eg, dim lighting, inactivity, being alone) and in the evening or nighttime [
         <a href="#rid4">
          4
         </a>
         ].
        </p>
        <p>
         The duration of the hallucination ranges from less than one minute to continuous [
         <a href="#rid1">
          1,4,5,8,38
         </a>
         ]. Most patients report a duration of several minutes. The frequency is variable; the majority of patients experience hallucinations multiple times a day or week [
         <a href="#rid1">
          1,5,23
         </a>
         ]. Some patients experience only a few isolated episodes.
        </p>
        <p>
         Associated symptoms depend upon the underlying disorder producing the visual loss. As examples, strokes involving the visual pathways produce visual field loss and sometimes other neurologic deficits, while macular degeneration and diabetic retinopathy produce loss of visual acuity without neurologic deficits [
         <a href="#rid23">
          23
         </a>
         ]. Patients with CBS typically do not have an abnormal mental status or other neurologic deficits [
         <a href="#rid22">
          22
         </a>
         ]. However, a syndrome of agitated delirium, visual hallucinations, and hemianopia can also be produced by lesions (usually stroke) affecting the medial aspect of the occipital lobe, the parahippocampal gyrus, and the hippocampus [
         <a href="#rid23">
          23
         </a>
         ]. This can be difficult to distinguish from acute toxic metabolic encephalopathy. (See
         <a class="medical medical_review" href="/z/d/html/5255.html" rel="external">
          "Approach to the patient with visual hallucinations", section on 'Metabolic encephalopathy'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h1">
          DIFFERENTIAL DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Other etiologies of visual hallucinations include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Migraine aura
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Epileptic seizures
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Neurodegenerative disease, especially dementia with Lewy bodies and Parkinson disease
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Drugs, alcohol intoxication or withdrawal (
         <a class="graphic graphic_table graphicRef51079" href="/z/d/graphic/51079.html" rel="external">
          table 1
         </a>
         )
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Metabolic encephalopathy, delirium
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Peduncular hallucinosis
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Narcolepsy
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Psychiatric disease
        </p>
        <p>
        </p>
        <p>
         In general, CBS is distinguished from these entities by the absence of other neurologic deficits and by the presence of known ocular disease. Characteristics of the hallucinations and associated symptoms can also help distinguish these causes from the release hallucinations of CBS (
         <a class="graphic graphic_table graphicRef73106" href="/z/d/graphic/73106.html" rel="external">
          table 2
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/5255.html" rel="external">
          "Approach to the patient with visual hallucinations", section on 'Etiologies'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h1">
          DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         All patients with new-onset visual hallucinations should have a complete neurologic evaluation screening for cognitive impairment, parkinsonism, and other neurologic deficits, and the medication list should be reviewed. Drugs and medications associated with visual hallucinations are listed in the table (
         <a class="graphic graphic_table graphicRef51079" href="/z/d/graphic/51079.html" rel="external">
          table 1
         </a>
         ). In the absence of other neurologic abnormalities, and in the setting of known ocular disease (eg, macular degeneration), further diagnostic evaluation may not be required.
        </p>
        <p>
         By comparison, in the absence of known eye disease, a complete ophthalmologic evaluation with visual field testing should be performed. Brain magnetic resonance imaging is indicated if there is a visual field deficit or other focal neurologic deficit and for patients in whom the cause remains obscure.
        </p>
        <p>
         Patients with atypical features for CBS should also be further evaluated (
         <a class="graphic graphic_table graphicRef73106" href="/z/d/graphic/73106.html" rel="external">
          table 2
         </a>
         ). As examples:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients with abnormal mental status should be evaluated for psychiatric disease and/or delirium with laboratory studies and toxicology screen.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Associated auditory and/or tactile hallucinations are not consistent with CBS and suggest possible psychiatric disease, peduncular hallucinosis, narcoleptic hallucinations, or hearing or sensory loss.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Brief hallucinations that recur in a stereotyped fashion may indicate electroencephalography (EEG) to evaluate for possible seizure disorder.
        </p>
        <p>
        </p>
        <p>
         The general diagnostic approach to patients with visual hallucinations is discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/5255.html" rel="external">
          "Approach to the patient with visual hallucinations", section on 'Evaluation'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H650821630">
         <span class="h1">
          PROGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Release hallucinations often resolve if the underlying vision deficit is corrected, as with cataract removal [
         <a href="#rid9">
          9,39-41
         </a>
         ]. Hallucinations can also remit in some patients with either static or progressive vision loss. This appears to occur more often for patients with acute cerebral injury (stroke, surgery), in whom hallucinations often last only several days to a few weeks [
         <a href="#rid10">
          10,23,30,31
         </a>
         ]. However, such patients, as well as those with chronic ocular disease, can experience persistent hallucinations over several years. In one survey of patients with release hallucinations associated with macular disease, 75 percent had symptoms lasting five years or more [
         <a href="#rid14">
          14
         </a>
         ].
        </p>
        <p>
         Patients may be concerned that their symptoms may represent incipient dementia. We reassure patients that that is not the case. While one small series found that 26 percent of patients with CBS developed dementia over an average 33 months of follow-up [
         <a href="#rid42">
          42
         </a>
         ], further study is necessary to understand the magnitude of the associated risk [
         <a href="#rid22">
          22
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h1">
          TREATMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         Treatment is individualized according to the degree the patient is disturbed by their symptoms. While many find that symptoms have no significant impact on their life, up to a third of patients in one series reported that symptoms were distressing and had a negative effect on their quality of life [
         <a href="#rid14">
          14
         </a>
         ].
        </p>
        <p>
         I have found that patients are often relieved to know that treatment is an option. This reassurance may be all that is required [
         <a href="#rid5">
          5
         </a>
         ]. Some patients can be taught to suppress the hallucinations. Rapid eye movements from one target to another, particularly away from the affected visual field, or blinking may temporarily suppress the hallucination [
         <a href="#rid23">
          23,29,43
         </a>
         ]. Increasing arousal and visual stimuli (eg, increased illumination) and reducing social deprivation are also reported to be useful for individual patients, but these techniques have not been systematically studied [
         <a href="#rid44">
          44,45
         </a>
         ].
        </p>
        <p>
         Patients with continuous hallucinations or those with disturbing imagery may need specific treatment. While antipsychotic medications are sometimes cited as ineffective, others report benefit in individual patients [
         <a href="#rid3">
          3,33,41,46,47
         </a>
         ]. Newer (atypical) antipsychotic agents have fewer side effects than conventional agents, particularly in the older adult population. I have found that low doses of
         <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">
          olanzapine
         </a>
         or
         <a class="drug drug_general" data-topicid="9570" href="/z/d/drug information/9570.html" rel="external">
          quetiapine
         </a>
         provide benefit without significant side effects. In my experience, cholinesterase inhibitors (eg,
         <a class="drug drug_general" data-topicid="9383" href="/z/d/drug information/9383.html" rel="external">
          donepezil
         </a>
         ) also can provide some relief with minimal side effects [
         <a href="#rid48">
          48
         </a>
         ]. Antiseizure medications (
         <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">
          carbamazepine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9284" href="/z/d/drug information/9284.html" rel="external">
          clonazepam
         </a>
         ,
         <a class="drug drug_general" data-topicid="10035" href="/z/d/drug information/10035.html" rel="external">
          valproate
         </a>
         , and
         <a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">
          gabapentin
         </a>
         ) are also helpful in anecdotal reports [
         <a href="#rid35">
          35,40,49-53
         </a>
         ]. Individual case reports and small series also report benefit with
         <a class="drug drug_general" data-topicid="9046" href="/z/d/drug information/9046.html" rel="external">
          escitalopram
         </a>
         ,
         <a class="drug drug_general" data-topicid="9269" href="/z/d/drug information/9269.html" rel="external">
          cisapride
         </a>
         , and
         <a class="drug drug_general" data-topicid="10042" href="/z/d/drug information/10042.html" rel="external">
          venlafaxine
         </a>
         [
         <a href="#rid32">
          32,54,55
         </a>
         ]. Even partial relief may provide benefit for patients who desire treatment.
        </p>
        <p class="headingAnchor" id="H8">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Definition
         </strong>
         – Charles Bonnet syndrome (CBS) refers to a phenomenon of visual hallucinations occurring in patients with acquired vision loss affecting the eye or visual tracts in the optic nerve, chiasm, or brain.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Risk factors
         </strong>
         – CBS is most common among those with worse visual acuity and older age. Cognitive impairment and living conditions of sensory deprivation are not clearly risk factors. (See
         <a class="local">
          'Epidemiology'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical features
         </strong>
         – The hallucinations of CBS may be elementary (unformed flashes of light or geometric shapes) or complex (formed images often of animals, people, or scenes).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         These typically last a few minutes and usually recur frequently, daily or weekly. (See
         <a class="local">
          'Clinical features'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Diagnosis
         </strong>
         – The diagnosis of CBS is made when visual hallucinations occur in patients with vision loss in the absence of psychosis, delirium, or other causes.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         When there is no known history of vision loss, evaluation should include toxicology screen, ophthalmology consult, neurologic evaluation, visual field testing, and/or brain imaging. (See
         <a class="local">
          'Diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Management
         </strong>
         – Reassurance is important and may be all that is required; however, treatment should be offered as well.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Patients may be able to temporarily suppress hallucinations by closing their eyes or looking away.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         If hallucinations are troubling to patients, we suggest treatment trials with low doses of atypical antipsychotics, cholinesterase inhibitors, serotonin reuptake inhibitors, or antiseizure medications, all of which have anecdotal evidence of efficacy (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). The choice of medication is guided by side effect profiles and patient comorbidities. Even partial alleviation of the hallucinations can bring relief to patients with troubling hallucinations. (See
         <a class="local">
          'Treatment'
         </a>
         above.)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Scott IU, Schein OD, Feuer WJ, Folstein MF. Visual hallucinations in patients with retinal disease. Am J Ophthalmol 2001; 131:590.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jacob A, Prasad S, Boggild M, Chandratre S. Charles Bonnet syndrome--elderly people and visual hallucinations. BMJ 2004; 328:1552.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Siatkowski RM, Zimmer B, Rosenberg PR. The Charles Bonnet syndrome. Visual perceptive dysfunction in sensory deprivation. J Clin Neuroophthalmol 1990; 10:215.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Teunisse RJ, Cruysberg JR, Hoefnagels WH, et al. Visual hallucinations in psychologically normal people: Charles Bonnet's syndrome. Lancet 1996; 347:794.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nesher R, Nesher G, Epstein E, Assia E. Charles Bonnet syndrome in glaucoma patients with low vision. J Glaucoma 2001; 10:396.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Le JT, Peprah D, Agrón E, et al. Associations between Age-Related Eye Diseases and Charles Bonnet Syndrome in Participants of the Age-Related Eye Disease Study 2: Report Number 26. Ophthalmology 2022; 129:233.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Teunisse RJ, Cruysberg JR, Verbeek A, Zitman FG. The Charles Bonnet syndrome: a large prospective study in The Netherlands. A study of the prevalence of the Charles Bonnet syndrome and associated factors in 500 patients attending the University Department of Ophthalmology at Nijmegen. Br J Psychiatry 1995; 166:254.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Holroyd S, Rabins PV, Finkelstein D, et al. Visual hallucinations in patients with macular degeneration. Am J Psychiatry 1992; 149:1701.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Menon GJ, Rahman I, Menon SJ, Dutton GN. Complex visual hallucinations in the visually impaired: the Charles Bonnet Syndrome. Surv Ophthalmol 2003; 48:58.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Freiman TM, Surges R, Vougioukas VI, et al. Complex visual hallucinations (Charles Bonnet syndrome) in visual field defects following cerebral surgery. Report of four cases. J Neurosurg 2004; 101:846.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brown GC, Murphy RP. Visual symptoms associated with choroidal neovascularization. Photopsias and the Charles Bonnet syndrome. Arch Ophthalmol 1992; 110:1251.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Abbott EJ, Connor GB, Artes PH, Abadi RV. Visual loss and visual hallucinations in patients with age-related macular degeneration (Charles Bonnet syndrome). Invest Ophthalmol Vis Sci 2007; 48:1416.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Singh A, Subhi Y, Sørensen TL. Low awareness of the Charles Bonnet syndrome in patients attending a retinal clinic. Dan Med J 2014; 61:A4770.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cox TM, ffytche DH. Negative outcome Charles Bonnet syndrome. Br J Ophthalmol 2014; 98:1236.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Subhi Y, Schmidt DC, Bach-Holm D, et al. Prevalence of Charles Bonnet syndrome in patients with glaucoma: a systematic review with meta-analyses. Acta Ophthalmol 2021; 99:128.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schwartz TL, Vahgei L. Charles Bonnet syndrome in children. J AAPOS 1998; 2:310.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schultz G, Melzack R. The Charles Bonnet syndrome: 'phantom visual images'. Perception 1991; 20:809.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Teunisse RJ, Cruysberg JR, Hoefnagels WH, et al. Risk indicators for the Charles Bonnet syndrome. J Nerv Ment Dis 1998; 186:190.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lepore FE. Spontaneous visual phenomena with visual loss: 104 patients with lesions of retinal and neural afferent pathways. Neurology 1990; 40:444.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Adachi N, Watanabe T, Matsuda H, Onuma T. Hyperperfusion in the lateral temporal cortex, the striatum and the thalamus during complex visual hallucinations: single photon emission computed tomography findings in patients with Charles Bonnet syndrome. Psychiatry Clin Neurosci 2000; 54:157.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Teunisse RJ, Cruysberg JR, Hoefnagels WH, et al. Social and psychological characteristics of elderly visually handicapped patients with the Charles Bonnet Syndrome. Compr Psychiatry 1999; 40:315.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Russell G, Burns A. Charles Bonnet syndrome and cognitive impairment: a systematic review. Int Psychogeriatr 2014; :1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vaphiades MS, Celesia GG, Brigell MG. Positive spontaneous visual phenomena limited to the hemianopic field in lesions of central visual pathways. Neurology 1996; 47:408.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cogan DG. Visual hallucinations as release phenomena. Albrecht Von Graefes Arch Klin Exp Ophthalmol 1973; 188:139.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Burke W. The neural basis of Charles Bonnet hallucinations: a hypothesis. J Neurol Neurosurg Psychiatry 2002; 73:535.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Berrios GE, Brook P. The Charles Bonnet syndrome and the problem of visual perceptual disorders in the elderly. Age Ageing 1982; 11:17.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ffytche DH, Howard RJ, Brammer MJ, et al. The anatomy of conscious vision: an fMRI study of visual hallucinations. Nat Neurosci 1998; 1:738.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Baier B, de Haan B, Mueller N, et al. Anatomical correlate of positive spontaneous visual phenomena: a voxelwise lesion study. Neurology 2010; 74:218.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kölmel HW. Complex visual hallucinations in the hemianopic field. J Neurol Neurosurg Psychiatry 1985; 48:29.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Flint AC, Loh JP, Brust JC. Vivid visual hallucinations from occipital lobe infarction. Neurology 2005; 65:756.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lance JW. Simple formed hallucinations confined to the area of a specific visual field defect. Brain 1976; 99:719.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lang UE, Stogowski D, Schulze D, et al. Charles Bonnet Syndrome: successful treatment of visual hallucinations due to vision loss with selective serotonin reuptake inhibitors. J Psychopharmacol 2007; 21:553.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alao AO, Hanrahan B. Charles Bonnet syndrome: visual hallucination and multiple sclerosis. Int J Psychiatry Med 2003; 33:195.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Choi EJ, Lee JK, Kang JK, Lee SA. Complex visual hallucinations after occipital cortical resection in a patient with epilepsy due to cortical dysplasia. Arch Neurol 2005; 62:481.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chen CS, Lin SF, Chong MY. Charles Bonnet syndrome and multiple sclerosis. Am J Psychiatry 2001; 158:1158.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Komeima K, Kameyama T, Miyake Y. Charles Bonnet syndrome associated with a first attack of multiple sclerosis. Jpn J Ophthalmol 2005; 49:533.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Benson MT, Rennie IG. Formed hallucination in the hemianopic field. Postgrad Med J 1989; 65:756.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fernandez A, Lichtshein G, Vieweg WV. The Charles Bonnet syndrome: a review. J Nerv Ment Dis 1997; 185:195.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Levine AM. Visual hallucinations and cataracts. Ophthalmic Surg 1980; 11:95.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sonnenblick M, Nesher R, Rozenman Y, Nesher G. Charles Bonnet syndrome in temporal arteritis. J Rheumatol 1995; 22:1596.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Holroyd S, Rabins PV. A three-year follow-up study of visual hallucinations in patients with macular degeneration. J Nerv Ment Dis 1996; 184:188.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lapid MI, Burton MC, Chang MT, et al. Clinical phenomenology and mortality in Charles Bonnet syndrome. J Geriatr Psychiatry Neurol 2013; 26:3.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Issa BA, Yussuf AD. Charles bonnet syndrome, management with simple behavioral technique. J Neurosci Rural Pract 2013; 4:63.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Eperjesi F, Akbarali N. Rehabilitation in Charles Bonnet syndrome: a review of treatment options. Clin Exp Optom 2004; 87:149.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Plummer C, Kleinitz A, Vroomen P, Watts R. Of Roman chariots and goats in overcoats: the syndrome of Charles Bonnet. J Clin Neurosci 2007; 14:709.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tueth MJ, Cheong JA, Samander J. The Charles Bonnet syndrome: a type of organic visual hallucinosis. J Geriatr Psychiatry Neurol 1995; 8:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Coletti Moja M, Milano E, Gasverde S, et al. Olanzapine therapy in hallucinatory visions related to Bonnet syndrome. Neurol Sci 2005; 26:168.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ukai S, Yamamoto M, Tanaka M, Takeda M. Treatment of typical Charles Bonnet syndrome with donepezil. Int Clin Psychopharmacol 2004; 19:355.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hori H, Terao T, Shiraishi Y, Nakamura J. Treatment of Charles Bonnet syndrome with valproate. Int Clin Psychopharmacol 2000; 15:117.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Paulig M, Mentrup H. Charles Bonnet's syndrome: complete remission of complex visual hallucinations treated by gabapentin. J Neurol Neurosurg Psychiatry 2001; 70:813.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chaudhuri A. Charles Bonnet syndrome: an example of cortical dissociation syndrome affecting vision. J Neurol Neurosurg Psychiatry 2000; 69:704.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Görgens K, Liedtke M. [Charles Bonnet syndrome]. Psychiatr Prax 1998; 25:85.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hosty G. Charles Bonnet syndrome: a description of two cases. Acta Psychiatr Scand 1990; 82:316.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ranen NG, Pasternak RE, Rovner BW. Cisapride in the treatment of visual hallucinations caused by vision loss: the Charles Bonnet syndrome. Am J Geriatr Psychiatry 1999; 7:264.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bergman Y, Barak Y. Escitalopram for antipsychotic nonresponsive visual hallucinosis: eight patients suffering from Charles Bonnet syndrome. Int Psychogeriatr 2013; 25:1433.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 5250 Version 9.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11336933" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Visual hallucinations in patients with retinal disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15217875" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Charles Bonnet syndrome--elderly people and visual hallucinations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2144541" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : The Charles Bonnet syndrome. Visual perceptive dysfunction in sensory deprivation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8622335" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Visual hallucinations in psychologically normal people: Charles Bonnet's syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11711837" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Charles Bonnet syndrome in glaucoma patients with low vision.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34419554" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Associations between Age-Related Eye Diseases and Charles Bonnet Syndrome in Participants of the Age-Related Eye Disease Study 2: Report Number 26.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7728372" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : The Charles Bonnet syndrome: a large prospective study in The Netherlands. A study of the prevalence of the Charles Bonnet syndrome and associated factors in 500 patients attending the University Department of Ophthalmology at Nijmegen.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1443247" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Visual hallucinations in patients with macular degeneration.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12559327" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Complex visual hallucinations in the visually impaired: the Charles Bonnet Syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15540925" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Complex visual hallucinations (Charles Bonnet syndrome) in visual field defects following cerebral surgery. Report of four cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1381580" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Visual symptoms associated with choroidal neovascularization. Photopsias and the Charles Bonnet syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17325191" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Visual loss and visual hallucinations in patients with age-related macular degeneration (Charles Bonnet syndrome).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24495881" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Low awareness of the Charles Bonnet syndrome in patients attending a retinal clinic.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24825847" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Negative outcome Charles Bonnet syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32749787" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Prevalence of Charles Bonnet syndrome in patients with glaucoma: a systematic review with meta-analyses.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10646756" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Charles Bonnet syndrome in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1816537" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : The Charles Bonnet syndrome: 'phantom visual images'.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9521356" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Risk indicators for the Charles Bonnet syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2314586" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Spontaneous visual phenomena with visual loss: 104 patients with lesions of retinal and neural afferent pathways.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10803809" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Hyperperfusion in the lateral temporal cortex, the striatum and the thalamus during complex visual hallucinations: single photon emission computed tomography findings in patients with Charles Bonnet syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10428192" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Social and psychological characteristics of elderly visually handicapped patients with the Charles Bonnet Syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24848082" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Charles Bonnet syndrome and cognitive impairment: a systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8757013" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Positive spontaneous visual phenomena limited to the hemianopic field in lesions of central visual pathways.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4543235" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Visual hallucinations as release phenomena.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12397147" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : The neural basis of Charles Bonnet hallucinations: a hypothesis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7041567" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : The Charles Bonnet syndrome and the problem of visual perceptual disorders in the elderly.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10196592" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : The anatomy of conscious vision: an fMRI study of visual hallucinations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20083797" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Anatomical correlate of positive spontaneous visual phenomena: a voxelwise lesion study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3973619" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Complex visual hallucinations in the hemianopic field.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16157913" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Vivid visual hallucinations from occipital lobe infarction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/828866" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Simple formed hallucinations confined to the area of a specific visual field defect.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17446204" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Charles Bonnet Syndrome: successful treatment of visual hallucinations due to vision loss with selective serotonin reuptake inhibitors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12968834" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Charles Bonnet syndrome: visual hallucination and multiple sclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15767516" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Complex visual hallucinations after occipital cortical resection in a patient with epilepsy due to cortical dysplasia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11431243" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Charles Bonnet syndrome and multiple sclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16365804" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Charles Bonnet syndrome associated with a first attack of multiple sclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2616404" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Formed hallucination in the hemianopic field.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9091601" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : The Charles Bonnet syndrome: a review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7366949" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Visual hallucinations and cataracts.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7473492" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Charles Bonnet syndrome in temporal arteritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8600223" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : A three-year follow-up study of visual hallucinations in patients with macular degeneration.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23385362" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Clinical phenomenology and mortality in Charles Bonnet syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23546356" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Charles bonnet syndrome, management with simple behavioral technique.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15186205" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Rehabilitation in Charles Bonnet syndrome: a review of treatment options.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17428664" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Of Roman chariots and goats in overcoats: the syndrome of Charles Bonnet.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7710639" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : The Charles Bonnet syndrome: a type of organic visual hallucinosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16086130" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Olanzapine therapy in hallucinatory visions related to Bonnet syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15486523" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Treatment of typical Charles Bonnet syndrome with donepezil.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10759344" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Treatment of Charles Bonnet syndrome with valproate.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11430294" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Charles Bonnet's syndrome: complete remission of complex visual hallucinations treated by gabapentin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11184239" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Charles Bonnet syndrome: an example of cortical dissociation syndrome affecting vision.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9577852" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : [Charles Bonnet syndrome].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2260487" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Charles Bonnet syndrome: a description of two cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10438699" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Cisapride in the treatment of visual hallucinations caused by vision loss: the Charles Bonnet syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23676430" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Escitalopram for antipsychotic nonresponsive visual hallucinosis: eight patients suffering from Charles Bonnet syndrome.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
